Carregant...

Imaging Fibroblast Activation Protein Alpha improves diagnosis of metastatic Prostate Cancer with Positron Emission Tomography

PURPOSE: Metastatic castration resistant prostate cancer (mCRPC) is a lethal, heterogeneous disease with few therapeutic strategies that significantly prolong survival. Innovative therapies for mCRPC are needed, however, the development of new therapies relies on accurate imaging to assess metastasi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Hintz, Hallie M., Gallant, Joseph P., Vander Griend, Donald J., Coleman, Ilsa M., Nelson, Peter S., LeBeau, Aaron M.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7683011/
https://ncbi.nlm.nih.gov/pubmed/32636317
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-1358
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!